Autonomix Medical appointed Sandra Kalter as an independent director on September 14, 2026, expanding its board and adding medical-device regulatory experience. The appointment matters to investors because the company says she will provide strategic guidance as it advances its technologies, clinical development and discussions with potential industry partners.

Key Highlights

  • Sandra Kalter served as Medtronic’s Chief Regulatory Counsel and Vice-President from 2011 to 2025.
  • Kalter was a Strategic Advisor to iTolerance from 2025 to 2026.
  • She has not been appointed to any board committees at this time.

Autonomix Medical, Inc. (NASDAQ: AMIX) appointed Sandra Kalter as an independent director on September 14, 2026. The addition gives the board expertise in medical-device regulation, clinical matters, quality systems and technology evaluation as Autonomix advances its platform.

Kalter Adds Regulatory and Medical-Device Experience

Kalter held senior Leadership roles at Medtronic from 2005 to 2025, most recently serving as Chief Regulatory Counsel and Vice-President from 2011 to 2025. Her responsibilities included legal strategy covering global regulatory, quality, clinical, promotion and advertising, as well as medical safety. She also served as a Strategic Advisor to iTolerance from 2025 to 2026. Kalter has served on boards and committees including AdvaMed, the Food and Drug Law Institute and Breakthrough T1D. She participated in AdvaMed’s Legal Committee through 2025 and co-chaired its Advertising and Promotion Working Group and Off Label Working Group. She has not been appointed to any committees of Autonomix’s board at this time.

Board Role Supports Clinical Development

The company says Kalter’s experience will support its work toward clinical development and broader industry partnerships.